Description

(6Ar)-1-(4-Biphenylylmethoxy)-6Aβ,7,8,9,10,10Aα-Hexahydro-6,6-Dimethyl-9-Methylene-3-Pentyl-6H-Dibenzo[B,D]Pyran CAS NO 132213-93-5 is a complex, high-purity synthetic cannabinoid derivative of significant interest in advanced pharmaceutical research and development. This compound serves as a critical reference standard and key intermediate for the synthesis of novel therapeutic agents targeting the endocannabinoid system. It is primarily required by pharmaceutical R&D laboratories, analytical testing facilities, and fine chemical manufacturers engaged in developing next-generation medications for pain management, neurological disorders, and other specialized therapeutic areas.

Application

• Pharmaceutical Reference Standard: Used as a certified analytical standard for method development, validation, and quality control in drug testing and forensic analysis.
• Medicinal Chemistry Research: Serves as a crucial intermediate or lead compound in the synthesis and structure-activity relationship (SAR) studies of novel cannabinoid receptor agonists and antagonists.
• Preclinical Studies: Employed in in vitro and in vivo research to investigate pharmacological profiles, metabolic pathways, and therapeutic potential.
• Process Development: Acts as a benchmark in scaling up synthetic routes for the production of active pharmaceutical ingredients (APIs) within the cannabinoid class.
• Academic Research: Utilized in university and institutional laboratories for biochemical and neuropharmacological studies related to the endocannabinoid system.
• Impurity Profiling: Essential for identifying and quantifying related substances and degradation products in finished drug products and raw materials.

Basic Information

Product Name	(6Ar)-1-(4-Biphenylylmethoxy)-6Aβ,7,8,9,10,10Aα-Hexahydro-6,6-Dimethyl-9-Methylene-3-Pentyl-6H-Dibenzo[B,D]Pyran
CAS No.	132213-93-5
Molecular Formula	C34H40O2
Molecular Weight	480.68 g/mol
Synonyms	1-(4-Biphenylylmethoxy)-6Aβ,7,8,9,10,10Aα-hexahydro-6,6-dimethyl-9-methylene-3-pentyl-6H-dibenzo[b,d]pyran; (6aR)-1-([1,1'-Biphenyl]-4-ylmethoxy)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-9-methylene-3-pentyl-6H-dibenzo[b,d]pyran; Biphenylyl Methoxy Cannabinoid; CP 47,497 C8 Homologue; Cannabicyclohexanol C8 Homologue; CP-47,497-C8; 1-[(1,1'-Biphenyl-4-yl)methoxy]-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-9-methylene-3-pentyl-6H-dibenzo[b,d]pyran
EINECS	Contact for details

Quality Control

Our production of this high-purity cannabinoid derivative adheres to strict quality management systems. Every batch is subjected to comprehensive analytical testing, including HPLC, GC-MS, and NMR, to ensure identity, purity, and consistency. We provide a detailed Certificate of Analysis (COA) with each shipment, which includes batch-specific data on assay, impurity profiles, and residual solvents. Our quality commitment is designed to meet the exacting standards required for pharmaceutical R&D and analytical applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider using desiccants or storing under an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.